Sinopia, a San Diego, CA-based biotechnology company advancing novel therapeutics identified using its proprietary computational drug discovery platform, has been awarded a Phase II SBIR grant totaling $2.2M from the National Institute of Dental and Craniofacial Research.
The company intends to use the amount to advance its oral mucositis program to lead discovery and optimization.
Led by CEO Iman Famili, Sinopia Biosciences is a biotechnology company advancing novel therapeutics identified using its proprietary computational drug discovery platform. Its discovery platform combines high-throughput omics data, AI/machine learning, and network biology.
It is leveraging its computational drug discovery LEarn And DiScover (LEADS®) platform to identify promising oral mucositis therapeutic targets and candidates, which consists of artificial intelligence and machine learning (AI/ML) analysis of multi-omics data from relevant disease models to identify pathological signatures combined with high-throughput screening (HTS) and predictive modeling to identify and prioritize novel targets and compounds.
FinSMEs
12/09/2024